학술논문
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)
Document Type
Article
Author
Source
In ESMO Open March 2024 9(3)
Subject
Language
ISSN
2059-7029